Immunome, Inc. Capital Expenditures
Immunome, Inc. (IMNM) reported Capital Expenditures of $5.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-11
- Immunome, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $2.18M, a 140.44% increase year-over-year.
- Immunome, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $3.00M, a 18.09% decline year-over-year.
- Immunome, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $4.00M, a 255.15% increase year-over-year.
- Immunome, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $1.12M, a 27.49% decline year-over-year.
- Immunome, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $9.69M, a 35.02% increase from fiscal 2024.
- Immunome, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $7.17M, a 763.18% increase from fiscal 2023.
- Immunome, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $831.00K, a 235.08% increase from fiscal 2022.
- Immunome, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $248.00K, a 213.92% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $5.18M 10-Q · filed 2026-08-11 | $9.18M derived: sum of 3 quarters · filed 2026-08-11 | $10.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $3.00M 10-Q · filed 2026-05-12 | $7.00M derived: sum of 2 quarters · filed 2026-05-12 | $8.12M derived: sum of 3 quarters · filed 2026-05-12 | $9.02M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $5.12M derived: sum of 2 quarters · filed 2026-03-03 | $6.02M derived: sum of 3 quarters · filed 2026-08-11 | $9.69M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.02M derived: sum of 2 quarters · filed 2026-08-11 | $5.69M 10-Q · filed 2025-11-06 | $6.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $905.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.57M 10-Q · filed 2026-08-11 | $5.70M derived: sum of 3 quarters · filed 2026-08-11 | $7.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $3.67M 10-Q · filed 2026-05-12 | $4.79M derived: sum of 2 quarters · filed 2026-05-12 | $6.33M derived: sum of 3 quarters · filed 2026-05-12 | $8.67M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.67M derived: sum of 2 quarters · filed 2026-03-03 | $5.01M derived: sum of 3 quarters · filed 2026-03-03 | $7.17M 10-K · filed 2026-03-03 |
| 2024-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.88M derived: sum of 2 quarters · filed 2025-11-06 | $6.05M 10-Q · filed 2025-11-06 | $6.40M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.51M 10-Q · filed 2025-08-06 | $4.86M derived: sum of 3 quarters · filed 2025-08-06 | $4.89M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $2.16M 10-Q · filed 2025-05-12 | $2.51M derived: sum of 2 quarters · filed 2025-05-12 | $2.55M derived: sum of 3 quarters · filed 2025-05-12 | $2.89M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $349.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $385.00K derived: sum of 2 quarters · filed 2025-03-19 | $725.00K derived: sum of 3 quarters · filed 2025-03-19 | $831.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $376.00K derived: sum of 2 quarters · filed 2024-11-13 | $482.00K 10-Q · filed 2024-11-13 | $554.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $340.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $446.00K 10-Q · filed 2024-08-12 | $518.00K derived: sum of 3 quarters · filed 2024-08-12 | $518.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $106.00K 10-Q · filed 2024-05-14 | $178.00K derived: sum of 2 quarters · filed 2024-05-14 | $178.00K derived: sum of 3 quarters · filed 2024-05-14 | $348.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $72.00K derived: sum of 2 quarters · filed 2024-03-28 | $242.00K derived: sum of 3 quarters · filed 2024-03-28 | $248.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $170.00K derived: sum of 2 quarters · filed 2023-11-09 | $176.00K 10-Q · filed 2023-11-09 | $190.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $170.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $176.00K 10-Q · filed 2023-08-09 | $190.00K derived: sum of 3 quarters · filed 2023-08-09 | $216.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $6.00K 10-Q · filed 2023-05-05 | $20.00K derived: sum of 2 quarters · filed 2023-05-05 | $46.00K derived: sum of 3 quarters · filed 2023-05-05 | $54.00K derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $40.00K derived: sum of 2 quarters · filed 2023-03-16 | $48.00K derived: sum of 3 quarters · filed 2023-03-16 | $79.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $34.00K derived: sum of 2 quarters · filed 2022-11-14 | $65.00K 10-Q · filed 2022-11-14 | $111.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $39.00K 10-Q · filed 2022-08-05 | $85.00K derived: sum of 3 quarters · filed 2022-08-05 | $209.00K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $31.00K 10-Q · filed 2022-05-12 | $77.00K derived: sum of 2 quarters · filed 2022-05-12 | $201.00K derived: sum of 3 quarters · filed 2022-05-12 | $562.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $170.00K derived: sum of 2 quarters · filed 2022-03-28 | $531.00K derived: sum of 3 quarters · filed 2022-03-28 | $586.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $485.00K derived: sum of 2 quarters · filed 2021-11-15 | $540.00K 10-Q · filed 2021-11-15 | $607.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $361.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $416.00K 10-Q · filed 2021-08-16 | $483.00K derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | $55.00K 10-Q · filed 2021-05-12 | $122.00K derived: sum of 2 quarters · filed 2021-05-12 | ||
| 2019-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $233.00K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $166.00K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |